Back to Search
Start Over
Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study
- Source :
- BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (7), pp.1406-1414. ⟨10.1016/j.bbmt.2018.04.008⟩
- Publication Year :
- 2018
- Publisher :
- HAL CCSD, 2018.
-
Abstract
- International audience; Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared with de novo AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell transplantation (HCT); thus, this large systemic analysis of the European Society for Blood and Bone Marrow Transplantation registry was performed. This study included 4997 patients with sAML who received HCT from 2000 to 2016. In univariate analysis the 2-year cumulative incidence of chronic graft-versus-host disease (GVHD), relapse, and nonrelapse mortality (NRM) were 33.5% (95% confidence interval [Cl], 32% to 34.9%), 33.7% (95% CI, 32.3% to 35.1%), and 27.5% (95% CI, 26.1% to 28.7%), respectively. Overall survival (OS), leukemia-free survival (LFS), and GVHD-free, relapse-free survival (GRFS) at 2 years were 44.5% (95% CI, 43% to 46%), 38.8% (95% CI, 37.4% to 40.3%), and 27.2% (95% Cl, 25.9% to 28.6%), respectively. In multivariate analysis, patients receiving myeloablative regimens had decreased relapse (hazard ratio, .859; 95% CI, .761 to .97; P = .01), higher NRM (hazard ratio, 1.175; 95% CI, 1.03 to 1341; P = .02), and no differences in OS, LFS, and GRFS compared with patients receiving reduced-intensity conditioning regimens. Active disease, adverse cytogenetics, older age, Karnofsky performance status (
- Subjects :
- Adult
Male
medicine.medical_specialty
Secondary
Transplantation Conditioning
Adolescent
medicine.medical_treatment
[SDV]Life Sciences [q-bio]
Medizin
Hematopoietic stem cell transplantation
Young Adult
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Secondary Acute Myeloid Leukemia
Cumulative incidence
ddc:610
Aged
Bone Marrow Transplantation
Aged, 80 and over
Acute leukemia
Univariate analysis
Transplantation
Acute myeloid leukemia
Toxicity
business.industry
Hazard ratio
Hematopoietic Stem Cell Transplantation
Hematology
Middle Aged
Confidence interval
3. Good health
Allogeneic stem cell transplantation
Europe
Antileukemic effect
Leukemia, Myeloid, Acute
Treatment Outcome
030220 oncology & carcinogenesis
Female
business
030215 immunology
Conditioning
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (7), pp.1406-1414. ⟨10.1016/j.bbmt.2018.04.008⟩
- Accession number :
- edsair.doi.dedup.....36572865231186cade8c33a61a3ec736